{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:01:45Z","timestamp":1781784105431,"version":"3.54.5"},"reference-count":71,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold><jats:italic>Background:<\/jats:italic><\/jats:bold>Neurofibromatosis type 1 (NF1) is a common single-gene disorder. A multidisciplinary approach to the management of NF1 patients is necessitated by the heterogeneity of clinical manifestations. Although multidisciplinary paediatric clinics have been well established, there is a dearth of such resources for adults with NF1. Herein we report our one-year institutional experience with a multidisciplinary adult NF1 clinic.<jats:bold><jats:italic>Methods:<\/jats:italic><\/jats:bold>A multidisciplinary team was assembled, and an NF Patient Registry Initiative questionnaire was adapted to collect patient-reported data during clinics. Multiple databases were searched to identify publications pertaining to the experience of other multidisciplinary NF1 clinics focusing on adult patients. Data on patient epidemiology and clinical staff were compared to our data.<jats:bold><jats:italic>Results:<\/jats:italic><\/jats:bold>A total of 77 patients were scheduled, and 68 attended the clinic, of whom 66 completed the intake questionnaire. The demographic and clinical data from this Canadian population are mostly consistent with previous reports, with some exceptions. Clinical data related to immune system involvement such as asthma, airway\/breathing-related difficulties or allergies were striking in our NF1 population. Six relevant published reports of other NF1 clinics were identified. Reports from these studies pertained to periods ranging from 10 to 38 months, and the number of adults assessed ranged from 19 to 177 patients.<jats:bold><jats:italic>Conclusions:<\/jats:italic><\/jats:bold>The structure of our clinic and the patient volume are comparable to those of other established centres found in the literature. Our data offer valuable cross-sectional prevalence statistics in the Canadian population. The patient-reported data concerning involvement of the immune system contribute to an emerging recognized medical concern within the NF1 population and warrant further clinical and basic investigation.<\/jats:p>","DOI":"10.1017\/cjn.2016.326","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T08:32:42Z","timestamp":1478593962000},"page":"577-588","source":"Crossref","is-referenced-by-count":7,"title":["Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic"],"prefix":"10.1017","volume":"44","author":[{"given":"Alireza","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber","family":"Ghadakzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolyn","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kongkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zadeh","family":"Gelareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"S0317167116003267_ref53","doi-asserted-by":"publisher","DOI":"10.1086\/320121"},{"key":"S0317167116003267_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1195-2"},{"key":"S0317167116003267_ref4","first-page":"575","article-title":"National Institutes of Health Consensus Development Conference","volume":"45","year":"1988","journal-title":"Arch Neurol"},{"key":"S0317167116003267_ref64","first-page":"1","volume-title":"Clin Genet","volume":"70","author":"Trov\u00f3-Marqui","year":"2006"},{"key":"S0317167116003267_ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-007-9101-8"},{"key":"S0317167116003267_ref14","doi-asserted-by":"publisher","DOI":"10.2165\/11630950-000000000-00000"},{"key":"S0317167116003267_ref68","unstructured":"Nantes University Hospital. Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 (NF1\u2013QDV); 2016. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01851135."},{"key":"S0317167116003267_ref71","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36530"},{"key":"S0317167116003267_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.137.11.1421"},{"key":"S0317167116003267_ref17","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"S0317167116003267_ref5","first-page":"E47","article-title":"The neurofibromatoses, part 1: NF1","volume":"6","author":"Lu-Emerson","year":"2009","journal-title":"Rev Neurol Dis"},{"key":"S0317167116003267_ref31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03543.x"},{"key":"S0317167116003267_ref21","first-page":"135","article-title":"Epidemiological analysis of neurofibromatosis type 1 in a reference hospital in Rio de Janeiro State [in Portuguese]","volume":"67","author":"Bonalumi Filho","year":"2010","journal-title":"Rev Bras Med"},{"key":"S0317167116003267_ref38","first-page":"371","article-title":"Cognitive dysfunction and emotional disturbances in children with neurofibromatosis type one (Recklinghausen\u2019s disease): review of the literature [in Polish]","volume":"39","author":"Trzcinska","year":"2005","journal-title":"Psychiatr Pol"},{"key":"S0317167116003267_ref36","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/111.6.1355"},{"key":"S0317167116003267_ref19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2340\/00015555-0005","article-title":"Neurofibromatosis 1\/Noonan syndrome associated with Hashimoto\u2019s thyroiditis and vitiligo","volume":"86","author":"Yalcin","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"S0317167116003267_ref52","first-page":"2085","article-title":"Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1","volume":"27","author":"Friedrich","year":"2007","journal-title":"Anticancer Res"},{"key":"S0317167116003267_ref1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2006.045906"},{"key":"S0317167116003267_ref33","doi-asserted-by":"publisher","DOI":"10.1177\/088307380201700802"},{"key":"S0317167116003267_ref66","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03400060099039"},{"key":"S0317167116003267_ref27","first-page":"134","article-title":"The Cardinal Glennon Children\u2019s Hospital Neurofibromatosis Clinic model","volume":"1","author":"Beckman","year":"1988","journal-title":"Neurofibromatosis"},{"key":"S0317167116003267_ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-18"},{"key":"S0317167116003267_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-009-1024-2"},{"key":"S0317167116003267_ref29","doi-asserted-by":"publisher","DOI":"10.1177\/088307389300800421"},{"key":"S0317167116003267_ref24","first-page":"197","article-title":"A clinical study of type 1 neurofibromatosis in north west England","volume":"36","author":"McGaughran","year":"1999","journal-title":"J Med Genet"},{"key":"S0317167116003267_ref54","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-109"},{"key":"S0317167116003267_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.2006.00579.x"},{"key":"S0317167116003267_ref61","first-page":"129","article-title":"Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells","volume":"17","author":"Riccardi","year":"1981","journal-title":"Birth Defects Orig Artic Ser"},{"key":"S0317167116003267_ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1531003506296488"},{"key":"S0317167116003267_ref44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1755"},{"key":"S0317167116003267_ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35982"},{"key":"S0317167116003267_ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s002340050814"},{"key":"S0317167116003267_ref56","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12611"},{"key":"S0317167116003267_ref30","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2005000900020"},{"key":"S0317167116003267_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2012.12.002"},{"key":"S0317167116003267_ref3","volume-title":"GeneReviews\u00ae","author":"Friedman","year":"1993\u20132016"},{"key":"S0317167116003267_ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000337548"},{"key":"S0317167116003267_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70063-8"},{"key":"S0317167116003267_ref26","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2012.85"},{"key":"S0317167116003267_ref58","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181bf15e3"},{"key":"S0317167116003267_ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30394"},{"key":"S0317167116003267_ref48","first-page":"949","article-title":"Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images","volume":"23","author":"Friedrich","year":"2003","journal-title":"Anticancer Res"},{"key":"S0317167116003267_ref50","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6"},{"key":"S0317167116003267_ref57","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1016\/j.ymthe.2005.07.513","article-title":"970. p53 expression and serum IgE levels in patients with neurofibromatosis type 1","volume":"11","author":"Geller","year":"2005","journal-title":"Mol Ther"},{"key":"S0317167116003267_ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-005-0033-4"},{"key":"S0317167116003267_ref63","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490370314"},{"key":"S0317167116003267_ref69","unstructured":"University of Alabama at Birmingham. A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 (STARS); 2016. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00853580."},{"key":"S0317167116003267_ref55","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-254"},{"key":"S0317167116003267_ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2014.02.006"},{"key":"S0317167116003267_ref67","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660320053011"},{"key":"S0317167116003267_ref2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-3204"},{"key":"S0317167116003267_ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-005-1265-4"},{"key":"S0317167116003267_ref51","first-page":"1573","article-title":"International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis","volume":"62","author":"Ferner","year":"2002","journal-title":"Cancer Res"},{"key":"S0317167116003267_ref23","doi-asserted-by":"publisher","DOI":"10.2165\/11630950-000000000-00000"},{"key":"S0317167116003267_ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000327379"},{"key":"S0317167116003267_ref39","doi-asserted-by":"publisher","DOI":"10.1080\/09297049.2010.542746"},{"key":"S0317167116003267_ref60","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1961.01580070098010"},{"key":"S0317167116003267_ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-003-0010-3"},{"key":"S0317167116003267_ref65","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63233-6"},{"key":"S0317167116003267_ref37","doi-asserted-by":"publisher","DOI":"10.1097\/00004703-198606000-00009"},{"key":"S0317167116003267_ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35840"},{"key":"S0317167116003267_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(94)70122-9"},{"key":"S0317167116003267_ref25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2340\/0001555575136140","article-title":"Life expectancy, mortality and prognostic factors in neurofibromatosis type 1: a twelve-year follow-up of an epidemiological study in G\u00f6teborg, Sweden","volume":"75","author":"Zoller","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"S0317167116003267_ref70","unstructured":"University of Alabama at Birmingham. A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1-Related Plexiform Neurofibromas (Protocol 102); 2016. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00634270."},{"key":"S0317167116003267_ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2007.01003.x"},{"key":"S0317167116003267_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(89)80137-4"},{"key":"S0317167116003267_ref59","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711190402"},{"key":"S0317167116003267_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N"},{"key":"S0317167116003267_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2006.01.005"},{"key":"S0317167116003267_ref47","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2008.061051"},{"key":"S0317167116003267_ref7","first-page":"160","article-title":"An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age","volume":"77","author":"McKeever","year":"2008","journal-title":"Ulster Med J"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167116003267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T20:25:47Z","timestamp":1692563147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167116003267\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0317167116003267"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2016.326","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]}}}